مباشر
CellMechanism of lipid transfer by bridge-like protein VPS13A and the scramblase XKCellGregory J. Hannon (1964–2026)FierceBiotechLilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’Endpoints NewsBiopharma’s 2025 industry pay report; Parabilis sets industry record IPO; and moreClinical OMICsLong-Read DNA Test Could Replace 15 Existing Tests for Rare Diseases10x Genomics Blog10x Genomics (TXG) Stock Valuation After Recent Surge In Returns - simplywall.stClinical OMICsMaternal Blood Test Allows Comprehensive Genetic Fetal ScreeningEndpoints NewsMerck brings Welireg-Keytruda combo to treat kidney cancerFDA News ReleasesFDA Clears First Over-the-Counter Continuous Glucose Monitor for ChildrenClinical OMICsFrom Multi-Omics to Digital Twins: A Data-Driven Future for Precision MedicineClinical OMICsAge-Related Mutations in Brain Immune Cells Linked to Alzheimer’s InflammationClinical OMICsPaper Mills and the Fight Against Scientific Fraud
BioWorld ١٠ مارس ٢٠٢٦

Sanofi licenses Sino Biopharm’s JAK/ROCK drug for $1.4B

Sanofi licenses Sino Biopharm’s JAK/ROCK drug for $1.4B

المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.